News
In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis, with a price target of $108.00. The company’s shares closed yesterday at $122.94. According to ...
In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis AG, with a price target of CHF89.00. The company’s shares opened today at CHF97.91. According to ...
Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...
Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...
Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...
In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...
BDS has performed consultancies for Roche, Eisai, EQTpartners, Remynd, Tactile, Earlybird, Sironax, Montis, and Abyssinia; and is a shareholder of Muna Tx. CH collaborates with Denali Therapeutics and ...
Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in ...
Li-Xuan Qin Employment: Sironax (I) Leadership: Sironax (I) Stock and Other Ownership Interests: Sironax Mithat Gonen Travel, Accommodations, Expenses: Genentech Andrea Cercek ...
SIR-2501 is under clinical development by Sironax and currently in Phase I for Neurodegenerative Diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results